Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.50 |
| ▸ | BRAF | P15056 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 3/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589268 | 0.86 | ABL1 (0.56) | ABL1 | |
| SCHEMBL24403508 | 0.84 | ABL1 (0.45) | ABL1BRAFSMN1; SMN2 | |
| SCHEMBL10265226 | 0.84 | BRAF (0.46) | BRAFSMN1; SMN2FLT3 | |
| SCHEMBL20922210 | 0.83 | ABL1 (0.45) | ABL1BRAFKIT | |
| SCHEMBL20922059 | 0.82 | BRAF (0.44) | ABL1BRAF | |
| SCHEMBL9610972 | 0.82 | ABL1 (0.60) | ABL1KDRKIT | |
| SCHEMBL20912688 | 0.82 | ABL1 (0.43) | ABL1BRAFKIT | |
| SCHEMBL20912748 | 0.81 | ABL1 (0.41) | ABL1BRAF | |
| SCHEMBL9609674 | 0.80 | ABL1 (0.51) | ABL1KIT | |
| SCHEMBL15510671 | 0.79 | ABL1 (0.50) | ABL1BRAFSMN1; SMN2FLT3KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231588-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. | 2020-07-23 | — | — | US | disclosed |
| US-20190031656-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2019-01-31 | — | — | US | disclosed |
| US-9278971-B2 | Substituted acetylenic pyrazolo[1,5-a]pyrimidines as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9029533-B2 | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | ARIAD PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20140288082-A1 | Bicyclic Heteroaryl Compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2014-09-25 | — | — | US | disclosed |
| US-8778942-B2 | Substituted acetylenic imidazo[1,2-A]pyrazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130196979-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8470851-B2 | Substituted acetylenic imidazo[1,2-A]pyridine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8114874-B2 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | PARK7, SNCA, HTT | ABL1 2649/4885BRAF 2710/4885SMN1; SMN2 19/4885 |
| US-20130196979-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885BRAF 2396/4885SMN1; SMN2 3086/4885 |
| US-20190031656-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | ABL1 122/4885BRAF 58/4885SMN1; SMN2 4760/4885 |
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | BRAF, RAF1, NRAS | ABL1 75/4885BRAF 1/4885SMN1; SMN2 1426/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885BRAF 2396/4885SMN1; SMN2 3086/4885 |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, MAPT, SNCA | ABL1 4036/4885BRAF 2579/4885SMN1; SMN2 9/4885 |
| US-20200231588-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885BRAF 2396/4885SMN1; SMN2 3086/4885 |
| US-20140288082-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885BRAF 2396/4885SMN1; SMN2 3086/4885 |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885BRAF 2396/4885SMN1; SMN2 3086/4885 |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885BRAF 2396/4885SMN1; SMN2 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.